ClinicalTrials.gg
RecruitingNCT06305208UK-ENDOMABUpdated Mar 15, 2024

A UK Registry for Metabolic and Bariatric Endoscopic Interventions

An observational study in Obesity and Diabetes Mellitus, Type 2, sponsored by Cleveland Clinic London. Recruiting at 1 site in United Kingdom. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2024-03-15.

Sponsored by Cleveland Clinic London · Observational

How we know

From the registry’s dates

  • Started Feb 2024; still recruiting 2 years 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
300
Ages
18 Years to 99 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 454 studies in Obesity with a site in United Kingdom — 94 open to participants now, 128 under way, 41 of them phase 3. Obesity · United Kingdom.

Planned enrollment
31st of 81
300 · median 130
Started
2024
with 19 others
Observational
81 of 454
24 open now
Primary completion
2034-02
later than 127 of 127 live
Registered
353rd of 454
by date

Among the 454 studies in Obesity with a site in United Kingdom, this one is the 31st largest by planned enrollment of the 81 observational ones that give a count, is one of 20 that started in 2024, is one of 81 observational ones, reaches primary completion later than 127 of the 127 other live ones, and was the 353rd registered.

Obesity

11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.

Browse Obesity studies →

Open to participants now

94 of the 454 studies in Obesity with a site in United Kingdom are open now. Recruiting first, the newest first:

89 more — sign in →

All 94 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 1,352 Obesity studies recruiting now, 382 (28%) set no upper age limit and 867 (64%) stop at 75 or younger; 169 take children under 18; 491 take healthy volunteers.

This study: 18 Years to 99 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 454 studies in Obesity with a site in United Kingdom, or all of them as a file.
02

Study summary

In the UK alone, obesity is a major health problem with more than one quarter of adults estimated to be obese. Obesity promotes the development of many serious diseases including diabetes, heart disease, kidney disease, and increased risk of some cancers. Patients living with obesity also suffer from significant symptoms that impact their life including shortness of breath, back pain, poor mobility, and poor mental health. Traditional methods to help lose weight include low calorie diets and increased exercise. These may be effective in the short-term, but due to powerful biological mechanisms they are hard to maintain over the long-term and most individuals are unable to achieve normal weight. This means many people may need bariatric surgery that is highly effective at lowering body weight, but it is associated with complications and not all patients will want or be able to undergo surgery. This has led to the development of many new obesity treatments that are completed with an endoscope. An endoscope is a thin flexible tube that has a camera at the end. It is inserted through the mouth and into the stomach and small bowel. There are various procedures that can be done at the time of endoscopy that have been shown to be effective with a low number of side-effects. These are still relatively new compared to more traditional treatments and only a small number of doctors can perform them within the UK. Due to these limitations, the aim of this registry is to obtain real-world information on the safety and effectiveness of these procedures across the UK. The investigators hope over time this will improve the knowledge of clinicians about treating obesity with endoscopy and support future access and funding to these treatments.

Read the detailed description

This is a national, multi-centre, prospective, UK registry that aims to determine the safety and efficacy of metabolic and bariatric endoscopic procedures used in the treatment of obesity and related complications. The investigators will do this by determining the effect of primary bariatric procedures (gastroplasty, intragastric balloons (IGB)), revisional bariatric procedures (Transoral outlet reduction endoscopy (TORe), gastroplasty revision), and primary metabolic procedures (Duodenal Mucosal Resurfacing (DMR)), completed by endoscopists within the UK.

The objective of this registry is to collect demographic, procedural and follow-up outcome data on the use of metabolic and bariatric endoscopic procedures in patients with obesity and/or obesity-related complications. This registry will provide real-life outcomes on the use of these novel endoscopic devices from multiple centres participating across the UK to provide longer-term safety and efficacy data. In addition, the registry will enable development of a UK-wide research network to support further research, innovation, and training into metabolic and bariatric endoscopy.

03

Conditions studied

  • Obesity
  • Diabetes Mellitus, Type 2
04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adult patients within the United Kingdom (UK) who have, or plan to, undergo a primary or revisional bariatric or metabolic endoscopic procedure for the treatment of obesity or metabolic disease in the UK

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Any patient undergoing a primary or revisional bariatric or metabolic endoscopic procedure.
  • Age ≥ 18 years old
  • Able to give written .

Exclusion criteria

Exclusion Criteria:

  • Any bariatric or metabolic endoscopic procedure performed outside the UK.
  • Any bariatric or metabolic endoscopic procedure not currently listed within the registry protocol or agreed by the steering committee.
  • Unable to provide written .
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
300 participants (estimated)
Target follow-up
5 Years
Patient registry
Yes

Groups and cohorts

  • Primary bariatric endoscopic procedures

    Device: Endoscopic gastric suturing · Device: Endoscopic gastric plication · Device: Intragastric balloon(s)

  • Revisional bariatric endoscopic procedures

    Device: Revisional gastroplasty · Device: Transoral outlet reduction endoscopy (TORe)

  • Primary metabolic endoscopic procedures

    Device: Duodenal mucosal resurfacing (DMR)

Interventions

  • DeviceEndoscopic gastric suturing

    Endoscopic suturing of the stomach to reduce volume and promote weight loss with either the Apollo Overstitch or Overstitch Sx system.

    Also known as: Endoscopic sleeve gastroplasty (ESG; Apollo Overstitch)

  • DeviceEndoscopic gastric plication

    Endoscopic plication of the stomach to reduce volume and promote weight loss with either the POSE or Endomina system.

    Also known as: Primary obesity surgery endoluminal (POSE), Endomina system

  • DeviceRevisional gastroplasty

    Endoscopic suturing or plication of the stomach among patients who have previously undergone gastroplasty, sleeve gastrectomy, or Roux-en-Y gastric bypass to restrict the stomach and promote weight loss

  • DeviceTransoral outlet reduction endoscopy (TORe)

    Reduction of the size of the gastro-jejunal anastomosis among patients who have previously undergone Roux-en-Y gastric bypass to promote weight loss. A variety of techniques may be used alone or in isolation including suturing (Apollo Overstitch), plication (POSE), argon photocoagulation, and endoscopic submucosal resection/dissection.

  • DeviceDuodenal mucosal resurfacing (DMR)

    Endoscopic ablation of the post-ampullary duodenal mucosal to enhance improvement in glycaemic control among patients with type 2 diabetes.

  • DeviceIntragastric balloon(s)

    The insertion of an intragastric implant into the stomach, which is subsequently filled with air or water to promote weight loss. Several intragastric balloons are available including Allurion, Heliosphere, Obalon, Orbera, and Spatz.

06

What researchers measure

Primary outcomes

  1. Total body weight loss percentage (TBWL%)

    For primary or revisional bariatric procedures: Percentage weight loss will be calculated using the following formula: TBWL% = \[(weight at the baseline-weight at the end of time period)/weight at baseline\] x 100

    Time frame: 6-months, 1-, 2-, 3-, 5-years

  2. Change in glycated haemoglobin (HbA1c; mmol/mol)

    For primary metabolic procedures

    Time frame: 6-months, 1-, 2-, 3-, 5-years

  3. Change in the number and dose of anti-diabetic medications

    For primary metabolic procedures

    Time frame: 6-months, 1-, 2-, 3-, 5-years

Secondary outcomes

  1. Procedure time (mins)

    Time frame: Baseline

  2. Inpatient stay (days)

    Time frame: 6-months, 1-, 2-, 3-, 5-years

  3. Adverse events

    Time frame: 30-day, 6-months, 1-, 2-, 3-, 5-years

  4. Change in systolic blood pressure measurements (mmHg)

    Time frame: 6-months, 1-, 2-, 3-, 5-years

  5. Change in diastolic blood pressure measurements (mmHg)

    Time frame: 6-months, 1-, 2-, 3-, 5-years

  6. Changes in number and dose of anti-hypertensive medications (n)

    Time frame: 6-months, 1-, 2-, 3-, 5-years

  7. Changes in low-density lipoprotein cholesterol (mmol/L)

    Time frame: 6-months, 1-, 2-, 3-, 5-years

  8. Changes in triglycerides (mmol/L)

    Time frame: 6-months, 1-, 2-, 3-, 5-years

  9. Changes in high-density lipoprotein cholesterol (mmol/L)

    Time frame: 6-months, 1-, 2-, 3-, 5-years

  10. Changes in total cholesterol (mmol/L)

    Time frame: 6-months, 1-, 2-, 3-, 5-years

  11. Changes in alanine transaminase (IU/L)

    Time frame: 6-months, 1-, 2-, 3-, 5-years

  12. Changes in aspartate aminotransferase (IU/L)

    Time frame: 6-months, 1-, 2-, 3-, 5-years

  13. Changes in Fibrosis-4 Index for Liver Fibrosis

    The Fibrosis-4 Index for Liver Fibrosis provides a probability score for the presence of hepatic fibrosis. It is based on age, ALT, AST, and platelet count. The range of the score is wide but there are two main cut-offs point for prediction of advanced fibrosis (\<1.3 and \>2.67). Higher scores indicate a higher likelihood of advanced fibrosis.

    Time frame: 6-months, 1-, 2-, 3-, 5-years

  14. Changes in non-alcoholic fatty liver disease fibrosis score

    The non-alcoholic fatty liver disease fibrosis score provides a probability score for the presence of hepatic fibrosis. It is based on age, body mass index, impaired fasting glucose, ALT, AST, albumin and platelet count. The range of the score is wide but there are two main cut-offs for prediction of advanced fibrosis (\<-1.455 and \>0.676). Higher scores indicate a higher likelihood of advanced fibrosis.

    Time frame: 6-months, 1-, 2-, 3-, 5-years

  15. Changes in weight (kg)

    Time frame: 6-months, 1-, 2-, 3-, 5-years

  16. Changes in body mass index (kg/m2)

    Time frame: 6-months, 1-, 2-, 3-, 5-years

  17. Changes in glycated haemoglobin (HbA1c; mmol/mol)

    Time frame: 6-months, 1-, 2-, 3-, 5-years

  18. Changes in number and dose of anti-diabetic medications (n)

    Time frame: 6-months, 1-, 2-, 3-, 5-years

  19. Changes in number and dose of anti-obesity medications (n)

    Time frame: 6-months, 1-, 2-, 3-, 5-years

  20. Changes in health-related quality of life scores (EuroQol-5D-5L)

    The EuroQol-5D-5L is a quality of life questionnaire that is composed of five questions scored 1-5 that do not have an arithmetic value and a visual analogue scale between 0-100. Participants are simply given a five digit code (e.g. 13455) and a visual analogue score (e.g. 78), which can then be interpreted through reference value sets in the corresponding country.

    Time frame: 6-months, 1-, 2-, 3-, 5-years

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2024 (actual). Primary completion is estimated for Feb 2034, 120 months after the start.

Of 796 non-industry observational studies under Obesity, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 106. This study's planned 120 months is above that.

Counting every sponsor, half of 842 studies reached it within 39 months; a quarter within 17 and three quarters within 96.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 5, 2024
First posted
Mar 12, 2024
StartActual
Feb 1, 2024
Primary completionEst.
Feb 1, 2034
CompletionEst.
Feb 1, 2039
Last update
Mar 15, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 15, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06305208
Lead sponsor
Cleveland Clinic London
Responsible party
Sponsor
First posted
Mar 12, 2024
Start date
Feb 1, 2024
Primary completion
Feb 1, 2034 (estimated)
Completion
Feb 1, 2039 (estimated)
Last update
Mar 15, 2024

Study contacts

Benjamin Norton, MD
Contact
cclendoscopyresearch@ccf.org
+442034237500
Fiona Makia
Contact
cclresearch@ccf.org
+442034237500
Rehan Haidry, MD
principal investigator · Cleveland Clinic London

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion